Report Summary 1. Industry Investment Rating No industry investment rating is provided in the report. 2. Core View The market is characterized by a structural trend. On January 19, the four major index futures contracts for the current month showed mixed performance. On the trading day, the total trading volume of index futures declined, indicating a decrease in investors' trading enthusiasm. The positions of the four major index futures also changed, with some increasing and some decreasing [1][2][3]. 3. Summary by Relevant Catalogs 3.1 Index Futures Data Tracking - **Closing Price and Fluctuation**: The closing prices of various index futures showed different degrees of increase or decrease. For example, the CSI 300 index closed at 4734.5, up 0.05%; the SSE 50 index closed at 3075.9, down 0.12%; the CSI 500 index closed at 8288, up 0.67%; and the CSI 1000 index closed at 8265.7, up 0.40% [1]. - **Basis**: The basis of different index futures and their contracts also varied. For instance, the basis of IF2602 was -1.66, and that of IH2602 was 0.46 [1]. - **Trading Volume and Open Interest**: The trading volume and open interest of each index futures contract changed. For example, the trading volume of IF2602 decreased by 5290 lots, and the open interest decreased by 1168 lots [1]. 3.2 Market Activity - **Trading Volume**: The total trading volume of index futures decreased. Specifically, the total trading volume of IF decreased by 34310 lots, IH by 18564 lots, IC by 21181 lots, and IM by 35971 lots [2]. - **Open Interest**: The total open interest of index futures also changed. The total open interest of IF decreased by 4289 lots, IH by 1610 lots, IC increased by 6196 lots, and IM increased by 1234 lots [3]. 3.3 Top 20 Member Positions The positions of the top 20 members in different index futures contracts changed. For example, in the IF2601 contract, the long - position decreased by 1007 lots, and the short - position decreased by 724 lots [5]. 3.4 Trend Intensity The trend intensity of IF and IH is 1, and that of IC and IM is also 1. The trend intensity ranges from - 2 to 2, with - 2 being the most bearish and 2 being the most bullish [6]. 3.5 Important Drivers - **A - share Market**: A - shares were in a shrinking and volatile state. The Shanghai Composite Index rose 0.29% to 4114 points, the Shenzhen Component Index rose 0.09%, the ChiNext Index fell 0.7%, and the total trading volume of A - shares was 2.73 trillion yuan, down from 3.06 trillion yuan the previous day [7]. - **Hong Kong Stock Market**: Hong Kong stocks opened lower and closed lower. The Hang Seng Index fell 1.05% to 26563.9 points, the Hang Seng Tech Index fell 1.24%, and the total trading volume was 2256.9 billion Hong Kong dollars, down from 2550.79 billion Hong Kong dollars the previous day [7]. - **Macroeconomic Data**: In 2025, China's GDP was 1401879 billion yuan, a 5% increase compared to the previous year. The national population at the end of 2025 was 1404890000, a decrease of 3390000 from the previous year, with a natural population growth rate of - 2.41‰ [7][8].

Core Viewpoint - The commercialization of ADC (Antibody-Drug Conjugates) drugs is reaching a turning point, highlighting a capacity gap in the industry as WuXi AppTec (HK02268) announces a significant acquisition of Easton Biopharma (HK01875) to enhance its production capabilities [1][4]. Group 1: Acquisition Details - WuXi AppTec plans to acquire approximately 773 million shares of Easton Biopharma at a price of HKD 4.000 per share, valuing the total equity at approximately HKD 30.91 billion [2]. - The offer price represents a significant premium of about 99% over the closing price of HKD 2.010 per share on December 22, 2025, and a 114.67% premium over the 30-day average closing price of HKD 1.860 per share [2]. - Easton Biopharma has a limited market presence, often referred to as a "zombie stock," with a typical daily trading volume of less than HKD 1 million [2]. Group 2: Business Synergy - The acquisition is driven by the business synergy between WuXi AppTec and Easton Biopharma, as the latter is one of the earliest developers of ADC drugs in China, although it has faced challenges with its ADC pipeline [3]. - Easton Biopharma's revenue from product sales has been increasing, with projected revenues of RMB 3.04 billion, RMB 6.30 billion, and RMB 8.77 billion for 2022, 2023, and 2024 respectively, indicating a shift towards profitability in 2024 [3]. Group 3: Production Capacity and Strategic Fit - Easton Biopharma possesses a large-scale GMP-compliant production facility and has established an integrated ADC platform, which aligns with WuXi AppTec's strategy to enhance production capacity [4][5]. - The geographical proximity of both companies in the Yangtze River Delta region is crucial for reducing technology transfer risks and achieving operational efficiency [1][5]. - WuXi AppTec anticipates significant growth, projecting a revenue increase of over 45% and a gross profit increase of over 70% for 2025, alongside a substantial rise in adjusted net profit [6].

Market Overview - The Hang Seng Index closed at 26,845 points, down 0.3%, while the Hang Seng China Enterprises Index fell 0.5% to 9,221 points[1] - Total turnover in the Hong Kong market was HKD 255.1 billion, a decrease of 12.2% from HKD 290.5 billion the previous Thursday[1] - Blue-chip stocks like Techtronic Industries (669 HK) and Li Ning (2331 HK) rose by 4.9% and 4.3%, respectively, while Pop Mart (9992 HK) and Alibaba Health (241 HK) fell by 5.6% and 5.2%[1] Economic Indicators - The U.S. NAHB housing market index for January was reported at 37, below last week's 39 and market expectations of 40[3] Sector Performance - In the automotive sector, AI-related stocks surged, with Cao Cao Chuxing (2643 HK) and Hesai (2525 HK) rising by 10.9% and 5.6% respectively[4] - The heavy truck sector benefited from a subsidy policy, with China National Heavy Duty Truck Group (3808 HK) and Weichai Power (2338 HK) increasing by 3%-4%[4] - Pop Mart faced allegations of labor exploitation, leading to a 5.6% drop in its stock price, marking a cumulative decline of 48% from its peak[4] Energy Sector Developments - The electricity equipment sector showed strong performance, with stocks like Dongfang Electric (1072 HK) and Harbin Electric (1133 HK) rising by 4.9% and 5.8% respectively[5] - The State Grid announced an expected fixed asset investment of RMB 4 trillion during the 14th Five-Year Plan, a 40% increase from the previous plan[5]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index closing at 26,563.90 points, down 281.06 points, a decrease of 1.05% [1] - The Hang Seng Tech Index closed at 5,749.98 points, down 72.20 points, a decrease of 1.24% [2] - Trading volume in the market was 225.7 billion HKD, continuing to shrink compared to the previous Friday [1] Company Focus - China Taiping (HK00966) saw a significant increase of over 6%, reaching its highest stock price since April 2019 [3] - The company announced that its annual profit attributable to shareholders is expected to increase by approximately 215% to 225% by the end of 2025, compared to the previous year [5] - The expected profit for the fiscal year 2024 is 8.432 billion HKD, attributed to improved net investment performance and a one-time impact from new corporate income tax policies introduced by the Chinese tax authorities [5] - JPMorgan's report indicated that small and medium-sized insurance stocks outperformed the market last year, with an average price increase of about 58%, reflecting growing optimism about emerging life insurance demand and macroeconomic recovery [5] - JPMorgan upgraded China Taiping's rating from "Underweight" to "Overweight," raising the target price from 9.4 HKD to 30 HKD based on confidence in the company's underwriting resilience and earnings growth visibility [5] Sector Performance - The technology sector saw more declines than gains, with Bilibili down over 6%, Alibaba down over 3%, and Kuaishou down over 2% [5] - Airline stocks performed well, with China Eastern Airlines rising over 9% [5] - Wind power stocks also showed strong performance, with Dongfang Electric up over 6% [5] - The biopharmaceutical sector experienced widespread declines, with WuXi Biologics down over 4% [5] - Cryptocurrency-related stocks faced significant declines, with OKLink down over 5% [5] Capital Flow - Southbound funds recorded a net purchase of over 2.2 billion HKD in Hong Kong stocks by the market close [6] Market Outlook - Guotai Junan Securities believes that as the domestic economy recovers and major overseas economies shift to accommodative monetary policies, H-shares will further highlight their valuation advantages [8] - The firm anticipates that ongoing reforms and improvements in the capital market will inject sustained vitality into the Hong Kong stock market, with liquidity expected to improve significantly by 2026 [8] - Tianfeng Securities maintains a cautiously optimistic mid-term outlook for the Hong Kong market, suggesting a focus on value stocks with growth potential, particularly in the technology and consumer sectors [8]

Market Overview - The Hong Kong stock market showed a weak performance today, with all three major indices closing lower. The Hang Seng Index fell by 1.05% to 26,563.90 points, the Tech Index dropped by 1.24% to 5,749.98 points, and the National Enterprises Index decreased by 0.94% to 9,134.45 points [1]. Aviation Sector - The aviation sector performed strongly today, with notable gains in airline stocks. China Eastern Airlines rose by 9.20%, China Southern Airlines increased by 6.29%, and Air China gained 3.76% [3][4]. - According to Huachuang Securities, the aviation industry is expected to show a clear recovery trend in 2025, with Spring Airlines reporting a 12.1% year-on-year increase in both capacity (ASK) and passenger turnover (RPK) [4]. Energy and Power Sector - The energy and power sector saw a collective rise, with companies like Dongfang Electric increasing by 6.38% and Harbin Electric by 5.46% [5]. - The market recognizes the value of power equipment companies as essential components of AI computing infrastructure, with significant investments expected in this sector by 2026 [5]. Pharmaceutical Sector - Pharmaceutical stocks generally retreated, with notable declines in companies such as Viva Biotech, which fell by 5.83%, and WuXi Biologics, which dropped by 4.83% [6][7]. - Despite the short-term pressure on stock prices, the fundamentals of the pharmaceutical research service industry are improving, with a double-digit growth in new orders for several CRO companies [7][8]. AI Application Sector - Stocks in the internet healthcare and AI application sectors continued to decline, with Ping An Good Doctor down by 4.41% and Ark Health by 3.75% [9][10]. - Analysts from CITIC Securities noted that the trend of accelerating commercialization in the AI application field remains unchanged, with ongoing product iterations indicating user growth and business model exploration [10]. Individual Stock Movements - Jinxin Fertility reported a 5.28% increase, attributed to continued improvement in its fourth-quarter operational data, with a narrowing decline in IVF cycles [12]. - New World Department Store China surged by 29.51% following recent personnel changes, including the appointment of new leadership [13].

Market Overview - The Hong Kong stock market indices collectively declined, with the Hang Seng Index falling by 1.05% to 26,563.90 points, the Hang Seng Tech Index down 1.24%, and the State-Owned Enterprises Index decreasing by 0.94% [1][5]. Sector Performance - Technology stocks experienced a mixed performance, with Bilibili dropping over 6%, Alibaba down more than 3%, Kuaishou falling over 2%, and other major players like Xiaomi, Meituan, Tencent, and JD.com declining over 1%. However, Baidu saw an increase of over 1% [1][5]. - Airline stocks led the gains, with China Eastern Airlines rising over 9%. The Spring Festival travel rush is expected to see 95 million passengers transported over 40 days, averaging 2.375 million daily, representing a year-on-year growth of 5.3% [2][6]. - Wind power stocks also performed well, with Dongfang Electric increasing over 6%. The State Grid Corporation of China anticipates a fixed asset investment of 4 trillion yuan during the 14th Five-Year Plan, a 40% increase compared to the previous plan, aimed at enhancing the new power system's supply chain [3][7]. - The biopharmaceutical sector saw a general decline, with WuXi Biologics dropping over 4%. Reports from the JPM conference indicated positive developments in the innovative drug sector, with multinational pharmaceutical companies and biotech firms announcing new pipeline strategies and significant transactions [3][7]. - Cryptocurrency-related stocks faced significant losses, with OKLink falling over 5%. The market experienced a collective drop due to renewed tariff threats from Europe and the U.S., leading to over 240,000 liquidations and a total liquidation amount of $864 million [3][7].

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Core Viewpoint - Daiwa reports that WuXi Biologics (02269) and WuXi AppTec (02268) plan to make a full acquisition offer for at least 60% of the shares of Easton Biopharma (01875) for a maximum cost of approximately 2.8 billion yuan, with the expectation that Easton Biopharma will maintain its listing status after the acquisition [1] Group 1 - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China [1] - The deal aims to enrich the project portfolio and expand the customer base for WuXi AppTec [1] - This acquisition is anticipated to strengthen WuXi AppTec's leading market position in the ADC contract research and manufacturing organization sector [1] Group 2 - Daiwa currently assigns a "Buy" investment rating to WuXi Biologics [1]

Group 1 - The core viewpoint of the article is that WuXi Biologics (02269) and WuXi AppTec (02268) have announced a comprehensive acquisition offer to acquire at least 60% of the shares of Easton Biopharma (01875) for a maximum price of approximately 2.8 billion yuan [1] - The acquisition is expected to help WuXi AppTec expand its business and gain additional operational production capacity in China, further enriching its project portfolio and expanding its customer base [1] - The acquisition is anticipated to solidify WuXi AppTec's leading market position in the field of ADC contract research and manufacturing organizations [1] Group 2 - Daiwa currently gives a "Buy" investment rating for WuXi Biologics [1]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].